NCT02416180View on ClinicalTrials.gov

Study to Evaluate Handling Errors in Usage of SERETIDE® Metered Dose Inhaler (MDI) (EVOHALER®) by Adult Subjects Currently Using the SERETIDE DISKUS® Inhaler

PHASE4CompletedINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

June 18, 2015

Primary Completion Date

August 20, 2015

Study Completion Date

August 20, 2015

Conditions
Asthma
Interventions
DEVICE

SERETIDE MDI

Commercially available SERETIDE MDI (EVOHALER) containing fluticasone propionate/salmeterol. Subjects will use MDI as 2 inhalations twice daily at the dose equivalent to their usual maintenance treatment of SERETIDE via DISKUS Inhaler.

DEVICE

Placebo DISKUS Inhaler

Placebo dry powder inhaler to be used to demonstrate the use of DISKUS inhaler at Visit 1

DEVICE

Placebo MDI

Clear liquid propellant inhaler to be used to demonstrate the use of MDI at Visit 2

Trial Locations (7)

10717

GSK Investigational Site, Berlin

10787

GSK Investigational Site, Berlin

13086

GSK Investigational Site, Berlin

23858

GSK Investigational Site, Reinfeld

60389

GSK Investigational Site, Frankfurt am Main

60596

GSK Investigational Site, Frankfurt am Main

63263

GSK Investigational Site, Neu-Isenburg

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02416180 - Study to Evaluate Handling Errors in Usage of SERETIDE® Metered Dose Inhaler (MDI) (EVOHALER®) by Adult Subjects Currently Using the SERETIDE DISKUS® Inhaler | Biotech Hunter | Biotech Hunter